|Cat. No. HS-439 003||200 µl specific antibody, lyophilized. Affinity purified with the immunogen. Albumin and azide were added for stabilization. For reconstitution add 200 µl H2O. Then aliquot and store at -20°C to -80°C until use.|
Immunocytochemistry (ICC) on 4% PFA fixed cells. Immunoreactivity is usually revealed by fluorescence. Some antibodies require special fixation methods. For details, please refer to the “Remarks” section.', $event)" style="cursor: help;">ICC: 1 : 1000 gallery
Immunohistochemistry (IHC) on 4% PFA perfusion fixed tissue with 24h PFA post fixation. Immunoreactivity is usually revealed by fluorescence or a chromogenic substrate. Some antibodies require special fixation methods or antigen retrieval steps. For details, please refer to the ”Remarks” section.', $event)" style="cursor: help;">IHC: 1 : 500 gallery
Immunohistochemistry (IHC-P) of formalin fixed, paraffin embedded (FFPE) tissue (some antibodies require special antigen retrieval steps, please refer to the ”Remarks” section). Immunoreactivity is usually revealed by fluorescence or a chromogenic substrate.', $event)" style="cursor: help;">IHC-P: 1 : 100 gallery
|Immunogen||Synthetic peptide corresponding to AA 527 to 547 from mouse CD19 (UniProt Id: P25918)|
Reacts with: mouse (P25918).
No signal: human (P15391), rat.
Other species not tested yet.
Indirect immunostaining of a formalin fixed paraffin-embedded mouse breast cancer model with rabbit anti-mouse CD19 (cat. no.: HS-439 003; DAB). Nuclei have been visualized by haematoxylin staining (blue).
CD19 (Cluster of Differentiation 19) is a B cell-restricted signal-transduction molecule that plays an important role in the regulation of development, activation, and differentiation of B-lymphocytes. CD19 is considered as a biomarker for B-cells because of its continued expression from very early B cell development stages, being evident already on pro-B cells and on all later B cell stages, until plasma cell terminal differentiation, when its expression is lost. In complex with CD21 (complement receptor-2), CD81 and CD225 (Leu-13), CD19 functions as a dominant signaling receptor on the surface of mature B cells (1). CD19 is instrumental in B cell homeostasis and lowers the threshold of B cell receptor crosslinking necessary to effect B-cell activation and sustain proliferation upon antigen encounter (2). Dysregulated CD19 expression has been implicated in several autoimmune diseases and CD19 is expressed in most acute lymphoblastic leukemias (ALL), chronic lymphocytic leukemias (CLL) and other B cell lymphomas (3). Therefore, CD19 has gained attention as a potential target in the therapy of B-cell malignancies (4).